KOSDAQBiotech & Pharma067370

SunBio

₩5,030▼ 1.37%2026-11-18 close
Market Cap
₩61.4B
Turnover
₩4,436,545
Volume
887 shares
Shares out.
12.2M
PER
32.4×
PBR
2.1×
EPS
₩156
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

SunBio: Earnings Slump in 2026 Amid China Competition

After returning to profit in 2025, SunBio posted an operating loss in the third quarter of 2026 as China competition, delayed U.S. approval and 2026 loan maturities weigh on the outlook.

  1. 1

    Revenue rose 57.5% year on year to KRW 13.7 billion in 2025, and operating profit of KRW 5.04 billion replaced the 2024 operating loss of KRW 533 million.

  2. 2

    Third-quarter 2026 revenue was KRW 1.89 billion, down 55.5% year on year, and the company recorded an operating loss of KRW 23.41 million.

  3. 3

    Product sales rose from KRW 6.4 billion to KRW 11.4 billion in 2025 while royalty revenue held at KRW 2.3 billion, according to an April 2026 IB Tomato report.

  4. 4

    A KRW 15 billion facility loan maturing in 2026 and the put option on the fourth convertible bond are the main liquidity items to watch.

  5. 5

    Company-level commentary cites the absence of U.S. patents and delayed approvals as factors weighing on results.

02

Business structure

SunBio, founded in 1997 and based in Incheon, focuses on PEG (polyethylene glycol) derivative materials and drug products built on them. P1PAL-20 and P1AM-5 both had export shares above 90% in 2024. Its flagship drug, MucoPEG, is a dry-mouth treatment that received U.S. FDA sales approval in November 2019.

In 2020 the company transferred technology and China marketing rights to a Chinese partner, and royalty income has followed since. Royalty revenue held at KRW 2.3 billion in 2025. As of the second quarter of 2026, the revenue mix was roughly 78% product sales and 22% royalties.

Cumulative revenue for the first three quarters of 2026 was KRW 28.0 million in product sales, KRW 2.23 billion in royalties and KRW 384.58 million in technology transfer revenue, based on the quarterly report as reported by Vegan News.

The Namdong Industrial Complex plants in Incheon were completed in August 2024, and the headquarters and factory relocation was completed in April 2025, according to IB Tomato. Competitively, quality gains and aggressive pricing by Chinese rivals have added price pressure in the PEG derivative market.

The business has three revenue streams, product sales, royalties and technology transfer, and fluctuations in royalty and technology fee income strongly drive profit swings.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.2B₩1.6B38.2%
2025Q4₩4.7B₩2.1B45.0%
2026Q1₩1.3B₩500M35.5%
2026Q2₩2.2B₩300M12.7%
2026Q3₩1.9B-₩23,405,952−1.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩7.4B₩200M₩900M2.6%3.6%79.9%
2023₩12.3B₩5.2B₩4.6B42.2%16.4%69.6%
2024₩8.7B-₩500M-₩100M−6.1%−0.4%125.3%
2025₩13.7B₩5B₩2.8B36.8%9.7%110.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue was KRW 7.42 billion in 2022, KRW 12.3 billion in 2023 (up 65.7% year on year), KRW 8.68 billion in 2024 (down 29.4%) and KRW 13.7 billion in 2025 (up 57.5%). Among 2022 to 2025, 2025 was the largest year and 2022 the smallest.

Operating profit rose from KRW 191 million in 2022 to KRW 5.19 billion in 2023, an increase of 2,619.8% year on year. The company swung to an operating loss of KRW 533 million in 2024 and back to an operating profit of KRW 5.04 billion in 2025.

Operating margins were 2.6% in 2022, 42.2% in 2023, -6.1% in 2024 and 36.8% in 2025. The 2024 loss coincided with a 29.4% drop in revenue. IB Tomato reported that the 2025 margin improvement reflected higher product sales together with lower R&D spending.

Net profit attributable to controlling shareholders was KRW 869 million in 2022, KRW 4.61 billion in 2023 (up 429.9%), a net loss of KRW 104 million in 2024 and KRW 2.79 billion in 2025.

Net income including non-controlling interests was reported as KRW 869 million, KRW 4.61 billion, a net loss of KRW 104 million and KRW 2.79 billion in the same years.

Quarterly revenue fell from KRW 4.25 billion in the third quarter of 2025 and KRW 4.68 billion in the fourth quarter (up 10.1% quarter on quarter) to KRW 1.29 billion in the first quarter of 2026 (down 72.4%).

Revenue recovered to KRW 2.24 billion in the second quarter of 2026 (up 73.5%) but reached only KRW 1.89 billion in the third quarter (down 15.5% quarter on quarter and down 55.5% year on year).

Quarterly operating profit went from KRW 1.62 billion in the third quarter of 2025 and KRW 2.11 billion in the fourth quarter to KRW 458 million in the first quarter of 2026 and KRW 284 million in the second quarter, and turned to an operating loss of KRW 23.41 million in the third quarter.

Net profit attributable to controlling shareholders swung to a loss of KRW 1.13 billion in the third quarter of 2026. The last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, totaled KRW 1.91 billion.

Operating cash flow was KRW 1.64 billion in 2022, KRW 4.97 billion in 2023, KRW 1.17 billion in 2024 and KRW 3.82 billion in 2025. The debt ratio fell to 110.2% at the end of 2025 from 125.3% in 2024.

05

Industry analysis

PEG derivatives are materials used in PEGylation, the process that extends how long biologic drugs stay in the body. A 2024 research note put the pegfilgrastim biosimilar market at roughly USD 800 million in 2020 and about USD 880 million in 2021, growth of around 10% a year.

The same note attributed growth to rising cancer prevalence and wider biosimilar adoption. The company's own commentary describes 2026 industry conditions as uncertain because Chinese rivals have improved quality and adopted aggressive pricing.

First-half 2026 standalone revenue fell 25.7% year on year, with lower technology fee and royalty income cited as the main cause. Business had rebounded from 2023 through 2025 on export strength and higher product sales, but in 2026 the rebound has been followed by a pricing-competition phase.

Compared with large biopharma peers in the same sector, which have greater production capacity and larger pipelines, SunBio is a small company built around materials and royalties.

In the U.S. market, the lack of patents and approval delays are cited as causes of weaker results, so U.S. approval status is a key variable for the sector outlook. The company presents expanding its high-value PEG derivative lineup as its response to price pressure.

06

Outlook

The company says it is focusing on expanding its high-value PEG derivative lineup and optimizing production at its new Namdong Industrial Complex plant in Incheon, according to its 2026 earnings commentary. The application for MucoPEG sales approval in Hong Kong has been completed.

A global joint research project on CloudPEG is being pursued, and the new plant is intended to strengthen market response. Artificial blood development had entered the preclinical stage as of an August 2023 report.

A KRW 15 billion loan falls due within 2026, and a company official told IB Tomato in April 2026 that the borrowing would most likely be extended. With facility investment complete, additional borrowing burden has reportedly eased.

Given that the 2025 full-year preliminary results were announced on February 9, 2026, the fourth-quarter 2026 preliminary results are expected in early February 2027. The 2026 annual business report must be filed by the end of March 2027.

Whether the new lineup and royalty flows show up in fourth-quarter 2026 results is the next checkpoint. The Hong Kong approval decision and progress on U.S. patents and approval remain variables with no announced timing.

07

Valuation

PER
32.4×
PBR
2.1×
ROE
6.9%
EPS
₩156
BPS
₩2,364
Dividend per share
₩0

Where the share price stands reflects a split view between the earnings base after the 2025 return to profit and the third-quarter 2026 swing to a loss. The last four quarters' net profit attributable to controlling shareholders totaled KRW 1.91 billion, a small earnings base relative to the market capitalization.

The price-to-book ratio sits at a level where market capitalization exceeds book equity, meaning a premium to net assets. The 2025 full-year return to profit restored the earnings base, in contrast to the loss-making 2024.

With the third quarter of 2026 back in loss, earnings-based multiples can move sharply with quarterly results. Cash dividend yield is low, so debt repayment and facility cost management appear to take priority over shareholder returns.

The debt ratio fell to 110.2% at the end of 2025, but loan maturities and the CB put option mean financial burden remains. Valuation interpretation depends on whether earnings recovery is sustained and whether the loan is extended, and these two variables drive the reading.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Product sales growth and return to profit

Operating profit returned to KRW 5.04 billion in 2025, and product sales rose from KRW 6.4 billion to KRW 11.4 billion in the same year, an increase of about 78%, according to IB Tomato. Royalty revenue held at KRW 2.3 billion, so the revenue base has broadened toward product sales. Lower R&D spending also contributed to the 2025 profit improvement.

Hong Kong filing and new product lineup

The Hong Kong sales approval application for MucoPEG has been completed, and a global joint research project on CloudPEG is underway. Expansion of the high-value PEG derivative lineup runs alongside, which supports diversification. However, the commercial results of the approval and joint research are not yet reflected in reported earnings.

Facility investment complete and easing debt burden

The main and production buildings at the Namdong Industrial Complex in Incheon were completed in August 2024, and the headquarters and factory relocation finished in April 2025. With facility investment concluded, the need for additional borrowing has reportedly declined, according to IB Tomato. The company also says production optimization is underway at the new plant.

09

Bear factors

China competition and pricing pressure

First-half 2026 standalone revenue fell 25.7% year on year and operating profit fell 43.3%. The company attributes this to lower technology fee and royalty income and to Chinese rivals' better quality and aggressive pricing.

In the third quarter of 2026, revenue of KRW 1.89 billion was followed by an operating loss of KRW 23.41 million.

Volatility in quarterly profit

Net profit attributable to controlling shareholders fell to KRW 318 million in the first quarter of 2026 (down 84.8% quarter on quarter), rebounded to KRW 631 million in the second quarter (up 98.3%), then swung to a net loss of KRW 1.13 billion in the third quarter.

The four-quarter total of KRW 1.91 billion reflects large swings between quarters. Profitability has not yet stabilized at the quarterly level.

Borrowing and liquidity pressure

Cash and cash equivalents were only KRW 2.8 billion at the end of 2025, while the portion of the KRW 15 billion facility loan due within a year was classified as current debt.

Property with a book value of KRW 38.2 billion is pledged against a maximum claim of KRW 31.2 billion from Woori Bank, and the company receives a guarantee of about KRW 4.4 billion from its CEO. The put option on the fourth convertible bond adds to the burden.

10

Risk factors

Patent and approval risk

Whether U.S. patents are secured and when approvals come through is the next point to check for a recovery in results. Uncertain timing for U.S. market entry limits how far the product and royalty structure can expand. The Hong Kong application is complete, but the decision timing has not been disclosed.

Borrowing and liquidity risk

The KRW 15 billion facility loan falls due within 2026. The company has indicated extension, but no confirmed disclosure has been made. The put option on the fourth convertible bond overlaps, which could increase cash flow pressure. Year-end 2025 cash of KRW 2.8 billion is reported to fall short of the amount due within one year.

Concentration and pricing risk

Revenue is concentrated in PEG derivative products and royalties, so changes in a single product or contract have a large effect on total results. If Chinese rivals' pricing strategy persists, both unit prices and volumes could face pressure. Royalty and technology fee income depends on contract terms and the counterparty's business schedule.

11

What to watch next

  1. By end-December 2026

    Check whether the KRW 15 billion facility loan is extended and any disclosure on the put option of the fourth convertible bond. The company has said the borrowing will most likely be extended.

  2. Early February 2027 (expected)

    Check the fourth-quarter and full-year 2026 preliminary results and operating margin level. The 2025 full-year preliminary results were announced on February 9, 2026.

  3. By March 31, 2027

    This is the filing deadline for the 2026 annual business report. Confirm how the new PEG derivative lineup and royalty flows are reflected in reported results.

  4. Timing undisclosed as of November 2026

    Watch the Hong Kong sales approval decision for MucoPEG and progress on U.S. patents and approval. The impact of the Hong Kong decision on the royalty and product revenue structure is the point to confirm.

12

Overall view

SunBio returned to profit in 2025, with revenue of KRW 13.7 billion and operating profit of KRW 5.04 billion, but quarterly revenue fell sharply from the first quarter of 2026 and the third quarter swung to an operating loss of KRW 23.41 million and a net loss attributable to controlling shareholders of KRW 1.13 billion.

Results hinge on PEG derivative product sales and royalty income, and the company attributes the first-half 2026 slowdown mainly to lower royalty and technology fee revenue. Strengths include higher product sales, the completed Hong Kong application, and easing borrowing pressure after facility investment ended.

Weaknesses include pricing pressure from Chinese competitors, the lack of U.S. patents and approval delays, and the KRW 15 billion facility loan maturity together with the CB put option.

The debt ratio fell to 110.2% at the end of 2025 from 125.3% in 2024, but liquidity with cash of KRW 2.8 billion is still reported as tight. Valuation depends on whether the earnings base built since the 2025 return to profit holds up through quarterly results.

The next checkpoints are the loan maturity treatment within 2026, the fourth-quarter 2026 preliminary results in early 2027, and the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. butler.works
  4. comp.wisereport.co.kr
  5. ssl.pstatic.net
  6. ssl.pstatic.net
  7. vegannews.co.kr
  8. m.thinkpool.com
  9. antwinner.com
  10. ibtomato.com
  11. comp.wisereport.co.kr
  12. jobkorea.co.kr
  13. comp.fnguide.com
  14. eugenefn.com
  15. bbn.kiwoom.com
  16. hanaw.com
  17. eugenefn.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis